Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
3.995
-0.015 (-0.37%)
Oct 26, 2026, 12:23 PM EDT - Market open
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 533 employees as of December 31, 2025. The number of employees increased by 165 or 44.84% compared to the previous year. That makes Vanda Pharmaceuticals the 19,599th largest employer in the world and 2,644th in the United States.
Employees
533
Change (1Y)
165
Growth (1Y)
44.84%
Revenue / Employee
$404,730
Profits / Employee
-$515,672
Market Cap
241.55M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 533 | 165 | 44.84% |
| Dec 31, 2024 | 368 | 165 | 81.28% |
| Dec 31, 2023 | 203 | -87 | -30.00% |
| Dec 31, 2022 | 290 | 12 | 4.32% |
| Dec 31, 2021 | 278 | -14 | -4.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Abeona Therapeutics | 226 |
| Rocket Pharmaceuticals | 202 |
| Fate Therapeutics | 161 |
| Cabaletta Bio | 158 |
| AC Immune | 122 |
| Ocugen | 116 |
| Larimar Therapeutics | 71 |
VNDA News
- 4 days ago - Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 - PRNewsWire
- 11 days ago - Vanda says anxiety drug failed main goal of late-stage study, puts program on hold - Reuters
- 11 days ago - Vanda Pharmaceuticals: Phase 3 study of VQW-765 did not meet primary endpoint - TheFly
- 11 days ago - Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program - PRNewsWire
- 24 days ago - Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting - PRNewsWire
- 26 days ago - Vanda Pharmaceuticals reports results from pivotal Phase III study of HETLIOZ - TheFly
- 26 days ago - Vanda Pharmaceuticals up 33% after Phase 3 Hetlioz study met primary endpoint - TheFly
- 26 days ago - Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder - PRNewsWire